For a 63‑year‑old woman with a T1mi papillary secretory breast carcinoma that is strongly hormone‑receptor positive, HER2‑negative, and has wide margins after breast‑conserving surgery, should sentinel lymph‑node biopsy be performed before whole‑breast radiotherapy, what is the minimum number of sentinel nodes to remove, what are the pros and cons, and what is the risk of axillary recurrence if SLNB is omitted?

Sentinel Lymph Node Biopsy in T1mi Breast Cancer

For a 63-year-old woman with T1mi papillary secretory breast carcinoma that is strongly hormone-receptor positive, HER2-negative, with wide margins after breast-conserving surgery, sentinel lymph node biopsy can be safely omitted before whole-breast radiotherapy, as this patient meets criteria for SLNB omission based on the most recent ASCO 2025 guidelines. 1

Evidence Supporting SLNB Omission

The 2025 ASCO guideline update specifically addresses this clinical scenario based on the SOUND and INSEMA randomized trials. Patients who are postmenopausal with pT1, grade 1 or 2, ductal carcinomas that are strongly hormone receptor–positive and HER2-negative are candidates for SLNB omission because they are unlikely to have cancer involvement of the lymph nodes. 1 Your patient's T1mi tumor (≤1mm invasive component) falls well within this favorable category.

Key Supporting Data:

• The SOUND trial demonstrated non-inferiority of omitting SLNB in carefully selected patients with tumors ≤2 cm and clinically negative axillae confirmed by ultrasound 1
• The INSEMA trial required whole-breast irradiation for all patients, and 50% received at least 80% of the prescribed breast dose to the level I axilla, which is assumed to be curative for low-volume nodal disease 1
• In T1 tumors, only 30% have involved lymph nodes, and this percentage is substantially lower for T1mi lesions 1

Minimum Number of Sentinel Nodes (If SLNB Performed)

If SLNB is performed, the median number of sentinel nodes removed should be 2, with a range typically of 1-3 nodes. 2 The identification rate should be at least 90% with a false-negative rate of 10% or less for an experienced team. 1

Technical Requirements:

• Combined approach using both vital blue dye and radioguided surgery achieves 98.7% detection rate versus 73.8% with dye alone or 94.1% with radioguided surgery alone 3
• At least 10 lymph nodes should be evaluated only if proceeding to complete axillary dissection, not for SLNB 1

Pros and Cons of SLNB in This Patient

Pros of Performing SLNB:

• Provides definitive pathologic staging information that may influence systemic therapy decisions 2
• In the overall elderly population with similar tumors, SLN status significantly affected use of adjuvant chemotherapy (though your patient's excellent prognostic features make chemotherapy unlikely) 2
• Micrometastases (≤2mm) are found in only 7% of cases and rarely associated with non-sentinel node involvement 4

Cons of Performing SLNB:

• SLNB is associated with up to 10% rate of lymphedema and chronic arm morbidity 1
• The procedure provides minimal additional prognostic information in this extremely favorable tumor biology 1
• Whole-breast radiotherapy will incidentally treat the lower axilla regardless, with 50% of patients receiving at least 80% of prescribed dose to level I axilla 1
• The false-negative rate of 8-12% means SLNB is not perfectly accurate even when performed 1, 3

Risk of Axillary Recurrence Without SLNB

The risk of axillary recurrence when omitting SLNB in this patient population is extremely low, estimated at less than 1-2% at 5-10 years. 1, 5

Supporting Evidence:

• In the SOUND trial with median follow-up, no significant difference in regional recurrence was observed between SLNB and no-SLNB groups 1
• Even in sentinel node-positive patients treated with mastectomy without any axillary therapy, the 10-year regional recurrence rate was only 3.8% 5
• For T1mi tumors specifically, the likelihood of nodal involvement is substantially lower than the 30% seen in general T1 populations 1
• Whole-breast radiotherapy provides incidental axillary coverage that is therapeutic for low-volume disease 1

Clinical Algorithm for Decision-Making

Step 1: Confirm Eligibility Criteria

• ✓ Postmenopausal status (age 63)
• ✓ T1mi tumor (≤1mm invasive)
• ✓ Strongly hormone receptor-positive
• ✓ HER2-negative
• ✓ Wide negative margins
• ✓ Breast-conserving surgery planned
• ✓ Whole-breast radiotherapy planned

Step 2: Axillary Ultrasound Assessment

Perform axillary ultrasound to rule out clinically suspicious nodes. 1 If a suspicious node is visualized, fine needle aspiration (FNA) is preferred over core biopsy due to lower complication rates and equivalent sensitivity. 1 If FNA is benign and concordant on ultrasound, proceed without SLNB.

Step 3: Shared Decision-Making Discussion

Present the patient with:

• Extremely low risk (<1%) of missing clinically significant axillary disease 1
• 10% risk of lymphedema/arm morbidity with SLNB 1
• Minimal impact on treatment decisions given favorable tumor biology 2
• Incidental axillary coverage from whole-breast RT 1

Step 4: Proceed with Treatment

Omit SLNB and proceed directly to whole-breast radiotherapy using either conventional fractionation (50 Gy in 25 fractions) or hypofractionation (40 Gy in 15 fractions), both of which provide incidental level I axillary coverage. 1

Important Caveats

This recommendation applies specifically to patients meeting ALL the favorable criteria listed above. 1 SLNB should still be performed if:

• The patient desires definitive pathologic staging despite counseling 1
• Axillary ultrasound shows suspicious nodes that cannot be adequately assessed 1
• The patient is considering partial breast irradiation instead of whole-breast RT (though this is not recommended for node-positive disease) 1
• The tumor has unfavorable features (high grade, lymphovascular invasion, younger age <50) that might warrant chemotherapy consideration 2

The papillary secretory histology in your patient is exceptionally favorable and further supports omission of SLNB. This rare subtype has excellent prognosis and minimal risk of nodal involvement.